Compare HBM & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HBM | JAZZ |
|---|---|---|
| Founded | 1927 | 2003 |
| Country | Canada | Ireland |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5B | 16.1B |
| IPO Year | 2005 | 2007 |
| Metric | HBM | JAZZ |
|---|---|---|
| Price | $26.56 | $237.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | $25.00 | ★ $217.57 |
| AVG Volume (30 Days) | ★ 2.9M | 757.9K |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.07% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 7.17 |
| Revenue | N/A | ★ $1,618,693,000.00 |
| Revenue This Year | $30.66 | $6.22 |
| Revenue Next Year | $14.54 | $7.68 |
| P/E Ratio | ★ $21.47 | $32.95 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.34 | $125.79 |
| 52 Week High | $32.15 | $266.38 |
| Indicator | HBM | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 48.38 | 42.86 |
| Support Level | $26.50 | $234.73 |
| Resistance Level | $29.01 | $242.66 |
| Average True Range (ATR) | 0.99 | 4.91 |
| MACD | -0.11 | -0.61 |
| Stochastic Oscillator | 38.29 | 37.97 |
Hudbay Minerals Inc is a copper-focused critical minerals company with three long-life operations and a pipeline of copper growth projects in Canada, Peru, and the United States. Its operating portfolio includes the Constancia mine in Cusco (Peru), the Snow Lake operations in Manitoba (Canada), and the Copper Mountain mine in British Columbia (Canada). Copper is the primary metal produced by the company, which is complemented by gold, zinc, silver, and molybdenum production. Hudbay's growth pipeline includes the Copper World project and the Mason project in the USA, and the Llaguen project in Peru. The company's reportable segments are: Peru, which generates the maximum revenue, Manitoba, British Columbia, and Arizona. Geographically, it generates maximum revenue from China and Canada.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.